Pr
Probiomed
Mexico City MXFounded 19701,200 employees
Private CapbiotechPrivateInfectious DiseaseImmunology
Platform: Biosimilar MX
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
2
FDA Approved
2
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Olpasacituzumab | PRO-9625 | Approved | 1 | SOS1 | ALLBCC | ||
| PRO-6778 | PRO-6778 | Preclinical | 1 | PSMA | ACC | ||
| PRO-4197 | PRO-4197 | Approved | 4 | SHP2 | Wilms | ||
| PRO-2782 | PRO-2782 | Preclinical | 1 | TYK2 | T2DSchizophrenia |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (4)